Kalaris Therapeutics Inc (KLRS)

Currency in USD
2.7500
-0.1750(-5.98%)
Real-time Data·
KLRS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
KLRS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.73002.9700
52 wk Range
2.280024.1500
Key Statistics
Prev. Close
2.925
Open
2.97
Day's Range
2.73-2.97
52 wk Range
2.28-24.15
Volume
8.79K
Average Volume (3m)
51.28K
1-Year Change
-83.82%
Book Value / Share
3.42
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
KLRS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
15.0000
Upside
+445.45%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Kalaris Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Kalaris Therapeutics Inc Company Profile

Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California.

Compare KLRS to Peers and Sector

Metrics to compare
KLRS
Peers
Sector
Relationship
P/E Ratio
−0.7x−4.5x−0.5x
PEG Ratio
-0.000.00
Price/Book
0.8x2.1x2.6x
Price / LTM Sales
-9.4x3.2x
Upside (Analyst Target)
-201.7%41.2%
Fair Value Upside
Unlock12.0%6.2%Unlock

Analyst Ratings

2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 15.0000
(+445.45% Upside)

Earnings

Latest Release
May 01, 2025
EPS / Forecast
-2.52 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

KLRS Income Statement

People Also Watch

17.09
SRPT
+23.30%
0.0948
OST
-8.41%
1.815
ONDS
-9.25%
2.88
INMB
-1.20%

FAQ

What Stock Exchange Does Kalaris Therapeutics Trade On?

Kalaris Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Kalaris Therapeutics?

The stock symbol for Kalaris Therapeutics is "KLRS."

What Is the Kalaris Therapeutics Market Cap?

As of today, Kalaris Therapeutics market cap is 52.74M.

What Is Kalaris Therapeutics's Earnings Per Share (TTM)?

The Kalaris Therapeutics EPS (TTM) is -10.39.

From a Technical Analysis Perspective, Is KLRS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Kalaris Therapeutics Stock Split?

Kalaris Therapeutics has split 1 times.

How Many Employees Does Kalaris Therapeutics Have?

Kalaris Therapeutics has 14 employees.

What is the current trading status of Kalaris Therapeutics (KLRS)?

As of 29 Jul 2025, Kalaris Therapeutics (KLRS) is trading at a price of 2.75, with a previous close of 2.93. The stock has fluctuated within a day range of 2.73 to 2.97, while its 52-week range spans from 2.28 to 24.15.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.